In executing on its expansion plans, eSense-Lab Limited (ASX:ESE) has entered into an exclusive sales agency agreement with Blue Science Solutions LLC for the distribution of its future terpene based sanitiser products in the United States.
Blue Science intend to fast-track and utilise its experience in the North American market to define the most suitable sales and distribution channels, as well as act as a local agent for eSense products in the US.
Benefits to the $10 million capped eSense include a cost-effective entry point to the US market via an established supply chain network, plus a viable solution logistically for entry of the company’s terpenes-based products into the world’s largest consumer networks.
Blue Science has agreed to minimum sales commitments of A$3 million for an initial 12-month period and A$10 million in product sales through its network over the first five years of the agreement, assuming the agreement is renewed after each 12-month term.
The agreement covers all terpenes-based products to be developed by eSense, both in conjunction with Blue Science and with other third parties in the cleaning and disinfecting solutions market segment.
The announcement this morning saw the company open 105% higher, extending the stock’s gain to more 1200% since its March lows.
In that time, eSense has introduced a new growth strategy, progressing its established businesses and expanding into new areas.
This new business model involves establishing joint venture partnership for the mutual development of products and to gain access to new markets. This strategy reduces a significant amount of costs associated with sales and distribution.
Collaboration to develop & sell a terpenes-based sanitiser product
Blue Science uses only natural ingredients to deliver non-toxic cleaning and disinfecting solutions that have applications across a variety of industries. It is the exclusive holder/licensee and applicant of several patents for sanitisation and disinfection products for FDA and EPA regulated industries.
Under the exclusive sales agency agreement announced today, Blue Science will have exclusivity to the US market — the world’s largest consumer base for terpene based products — subject to achieving the minimum eSense product sales. In the event these minimum sales targets are not achieved, the agreement will automatically become non-exclusive.
eSense management emphasised that it is still finalising product formulations, which are expected to take two to three months to complete, and pricing for terpenes-based sanitiser products in this market segment.
The company expect its first product — a terpenes-based sanitiser product — to be ready for manufacture in the next four to six months. It is anticipated that this product will only require a basic FDA registration as a no-rinse hand decontaminating solution. Meanwhile, the R&D team will finalise formulations for further products.
This exclusive sales agency agreement also provides eSense with access to a team of experienced scientists who have a proven track record of developing commercially viable products, including registered industrial professional hygienists, enzyme and organic chemists, and intellectual property attorneys, among others.
Another fact that won’t have gone unnoticed by eSense management is that Blue Science is an approved supplier to the IBM Rapid Supplier Connect initiative where it intends to introduce future products for sale through its supply chains.
The IBM Rapid Supplier Connect network is designed to provide support for supplier identity using blockchain technology. It aims to help buyers in the U.S. and Canadian healthcare and government sectors including hospitals, state procurement divisions, medical device makers, pharmacies and state and local governments, to find supplies and services
The network aims to help buyers in the US and Canadian healthcare and government sectors including hospitals, state procurement divisions, medical device makers, pharmacies and state and local governments, to find supplies and services in an unconventional marketplace with greater efficiency.
After averaging over US$2.5 million in revenue in its last two financial years, Blue Science has experienced an increase in demand for sanitiser products in line with a global shortage and expects significant revenue growth this year.
The commitment by Blue Science for product sales of A$10 million over five years should assist in increasing eSense’s earnings profile at the same time as reducing the costs associated in establishing a distribution and sales network in the US.
Under the terms of the agreement, eSense has agreed to issue 10 million CDIs in the capital of the company (approximately 2% of the issued and outstanding CDIs) to Blue Science (or its nominees) at a deemed issue price of $0.01 each in return for Blue Science agreeing to distribute its products through its networks. The agreement incorporates Blue Science receiving an arm’s-length standard commission on all sales.
Disclaimer– This content was produced and paid for by StocksDigital. The author may hold positions in the stocks mentioned in this publication, at the time of writing. The information contained in the publication and the links shared are general in nature and does not take into account your personal situation. You should consider whether the information is appropriate to your needs, and where appropriate, seek professional advice from a financial adviser. For errors that warrant correction please contact the editor at [email protected].
Strawman is Australia’s premier online investment club. Join for free to access independent & actionable recommendations from proven private investors.
© 2020 Strawman Pty Ltd. All rights reserved.
| Privacy Policy | Terms of Service | Financial Services Guide |
ACN: 610 908 211
